122 related articles for article (PubMed ID: 31485740)
1. Biopsy Grade Group as a reliable prognostic factor for BCR in Afro-Caribbean men with intermediate- and high-risk prostate cancer.
Perrot E; Seddik S; Gourtaud G; Eyraud R; Roux V; Moureaux C; Blanchet P; Brureau L
World J Urol; 2020 Jun; 38(6):1493-1499. PubMed ID: 31485740
[TBL] [Abstract][Full Text] [Related]
2. Overall, specific, and metastasis-free survival of Afro-Caribbean men with pathological Gleason 6 prostate cancer.
Mollard P; Perrot E; Blanchet P; Brureau L
Prostate; 2020 Mar; 80(4):329-335. PubMed ID: 31868959
[TBL] [Abstract][Full Text] [Related]
3. Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies).
Brureau L; Emeville E; Multigner L; Blanchet P
Prog Urol; 2018 Jun; 28(8-9):442-449. PubMed ID: 29789237
[TBL] [Abstract][Full Text] [Related]
4. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
[TBL] [Abstract][Full Text] [Related]
5. Presentation, follow-up, and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer: experiences of a high-volume UK centre.
Kum F; Beckmann K; Aya H; Singh S; Sandhu P; Sra S; Rusere J; Zisengwe G; Santaolalla A; Cathcart P; Challacombe B; Brown C; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):549-557. PubMed ID: 33558659
[TBL] [Abstract][Full Text] [Related]
6. Active surveillance in prostate cancer is possible for Afro-Caribbean population: Comparison of oncological outcomes with a Caucasian cohort.
Percot M; Robert G; Bladou F; Ferrière JM; Bensadoun H; Bernhard JC; Alezra E; Capon G; Sénéchal C; Gourtaud G; Brureau L; Roux V; Blanchet P; Eyraud R
Prog Urol; 2020 Sep; 30(10):532-540. PubMed ID: 32593527
[TBL] [Abstract][Full Text] [Related]
7. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.
Ritch CR; You C; May AT; Herrell SD; Clark PE; Penson DF; Chang SS; Cookson MS; Smith JA; Barocas DA
Urology; 2014 Jun; 83(6):1309-15. PubMed ID: 24746665
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
9. Extent of pelvic lymph node dissection improves early oncological outcomes for patients with high-risk prostate cancer without lymph node involvement after robot-assisted radical prostatectomy.
Morizane S; Honda M; Shimizu R; Tsounapi P; Teraoka S; Yumioka T; Yamaguchi N; Kawamoto B; Iwamoto H; Hikita K; Takenaka A
Int J Clin Oncol; 2022 Apr; 27(4):781-789. PubMed ID: 35076818
[TBL] [Abstract][Full Text] [Related]
10. Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study.
Meunier ME; Tantot J; Neuzillet Y; Ghoneim TP; Martin F; Taouil T; Vignac M; Baumert H; Vinh-Hung V; Dussaule-Duchatelle V; Lebret T; Sutter W; Molinié V
Prostate; 2019 Oct; 79(14):1640-1646. PubMed ID: 31376218
[TBL] [Abstract][Full Text] [Related]
11. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.
Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A
Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202
[TBL] [Abstract][Full Text] [Related]
12. Beyond D'Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier.
Gabriele D; Jereczek-Fossa BA; Krengli M; Garibaldi E; Tessa M; Moro G; Girelli G; Gabriele P;
Radiat Oncol; 2016 Feb; 11():23. PubMed ID: 26911291
[TBL] [Abstract][Full Text] [Related]
13. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic radical prostatectomy monotherapy, a more aggressive yet less invasive option, is oncologically effective in selected men with high-risk prostate cancer having only one D'Amico risk factor: experience from an Asian tertiary referral center.
Tai HC; Lai MK; Huang CY; Wang SM; Huang KH; Chen CH; Chung SD; Chueh SC; Yu HJ; Pu YS
J Endourol; 2014 Feb; 28(2):165-71. PubMed ID: 23987245
[TBL] [Abstract][Full Text] [Related]
15. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
Klaassen Z; Singh AA; Howard LE; Feng Z; Trock B; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Partin A; Han M; Freedland SJ
Cancer; 2015 May; 121(9):1414-21. PubMed ID: 25492369
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score.
Pollard ME; Hobbs AR; Kwon YS; Katsigeorgis M; Lavery HJ; Levinson A; Bernstein AN; Collingwood SA; Hall SJ; Jazayeri SB; Samadi DB
Oncol Res Treat; 2017; 40(9):508-514. PubMed ID: 28796995
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
Rossignol T; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
Prostate; 2021 Oct; 81(14):1091-1096. PubMed ID: 34320690
[TBL] [Abstract][Full Text] [Related]
18. Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
Izol V; Ok F; Aslan G; Akdogan B; Sozen S; Ozden E; Celik O; Muezzinoglu T; Turkeri L; Akdogan N; Baltaci S
Prostate; 2022 May; 82(7):763-771. PubMed ID: 35188993
[TBL] [Abstract][Full Text] [Related]
19. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
Schulman AA; Howard LE; Tay KJ; Tsivian E; Sze C; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ; Polascik TJ
Cancer; 2017 Nov; 123(21):4122-4129. PubMed ID: 28662291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
